Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | S100A4 | P26447 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | HPD | P32754 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375067 | 1.00 | KDM4E (0.41) | KDM4ES100A4MAPTRECQLKMT2A | |
| SCHEMBL7653325 | 0.82 | BRD4 (0.39) | MAPTRECQLKMT2AMCL1RXFP1 | |
| SCHEMBL24328520 | 0.81 | ALDH1A1 (0.39) | KDM4EMAPTKMT2ACYP3A4HPGD | |
| SCHEMBL30773544 | 0.81 | ALDH1A1 (0.39) | KDM4EMAPTKMT2ACYP3A4HPGD | |
| SCHEMBL22463118 | 0.81 | TDP1 (0.40) | S100A4MAPTRECQLKMT2AMCL1 | |
| SCHEMBL7659144 | 0.81 | MAPT (0.46) | MAPTRECQLKMT2AMCL1RXFP1 | |
| SCHEMBL31177224 | 0.81 | TP53 (0.53) | MAPTRECQLKMT2AMCL1RXFP1 | |
| SCHEMBL9404841 | 0.81 | TP53 (0.53) | MAPTRECQLKMT2AMCL1RXFP1 | |
| SCHEMBL30841549 | 0.81 | HIF1A (0.41) | S100A4MAPTRECQLKMT2AMCL1 | |
| SCHEMBL7656644 | 0.81 | HIF1A (0.41) | S100A4MAPTRECQLKMT2AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117263948-B | Compounds and conjugates thereof | 免疫医疗有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240239894-A1 | THERAPEUTIC BINDING MOLECULES | MEDIMMUNE LIMITED (GB) | 2024-07-18 | — | — | US | disclosed |
| US-20240239894-A1 | THERAPEUTIC BINDING MOLECULES | MEDIMMUNE LIMITED (GB) | 2024-07-18 | — | — | US | disclosed |
| CN-118240003-A | Compounds and conjugates thereof | 免疫医疗有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118221763-A | Compounds and conjugates thereof | 免疫医疗有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-113631196-B | Compounds and conjugates thereof | 免疫医疗有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117263948-A | Compounds and conjugates thereof | 免疫医疗有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-11795225-B2 | Therapeutic binding molecules | MEDIMMUNE LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11795225-B2 | Therapeutic binding molecules | MEDIMMUNE LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| CN-116829592-A | Therapeutic B7-H4 binding molecules | 免疫医疗有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2022053650-A1 | THERAPEUTIC B7-H4 BINDING MOLECULES | MEDIMMUNE LIMITED (GB) | 2022-03-17 | — | — | WO | disclosed |
| EP-3946464-A1 | COMPOUNDS AND CONJUGATES THEREOF | MedImmune Limited (GB) | 2022-02-09 | — | — | EP | disclosed |
| CN-113631196-A | Compounds and conjugates thereof | 免疫医疗有限公司 | 2021-11-09 | — | — | CN | disclosed |
| US-20210322401-A1 | COMPOUNDS AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2021-10-21 | — | — | US | disclosed |
| WO-2020200880-A1 | COMPOUNDS AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2020-10-08 | — | — | WO | disclosed |
| US-20200306243-A1 | COMPOUNDS AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2020-10-01 | — | — | US | disclosed |
| US-7435733-B2 | Mineralocorticoid receptor modulator compounds and methods, and pharmaceutical compositions containing these compounds | LIGAND PHARMACEUTICALS, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20070185102-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | LIGAND PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2006023158-A2 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | LIGAND PHARMACEUTICALS, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-5061795-A | ANTITUMOR AGENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1991-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185102-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | NR3C2, MC2R, NR3C1 | KDM4E 3549/4885S100A4 1673/4885MAPT 2468/4885 |
| US-11795225-B2 | Therapeutic binding molecules | EPCAM, IGSF11, FCGR3B | KDM4E 2990/4885S100A4 1312/4885MAPT 1237/4885 |
| US-20200306243-A1 | COMPOUNDS AND CONJUGATES THEREOF | TOP2A, TOP1, TOP2B | KDM4E 1693/4885S100A4 4339/4885MAPT 1295/4885 |
| US-20240239894-A1 | THERAPEUTIC BINDING MOLECULES | EPCAM, IGSF11, FCGR3B | KDM4E 2990/4885S100A4 1312/4885MAPT 1237/4885 |
| US-20210322401-A1 | COMPOUNDS AND CONJUGATES THEREOF | TOP2A, TOP1, TOP2B | KDM4E 1693/4885S100A4 4339/4885MAPT 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.